|
1
|
Carmeliet P: Angiogenesis in life, disease
and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Folkman J: Angiogenesis: an organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gaengel K, Genové G, Armulik A and
Betsholtz C: Endothelial-mural cell signaling in vascular
development and angiogenesis. Arterioscler Thromb Vasc Biol.
29:630–638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coultas L, Chawengsaksophak K and Rossant
J: Endothelial cells and VEGF in vascular development. Nature.
438:937–945. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling-in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Presta M, Dell’Era P, Mitola S, et al:
Fibroblast growth factor/fibroblast growth factor receptor system
in angiogenesis. Cytokine Growth Factor Rev. 16:159–178. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fagiani E and Christofori G: Angiopoietins
in angiogenesis. Cancer Lett. 328:18–26. 2013. View Article : Google Scholar
|
|
10
|
Bridges E, Oon CE and Harris A: Notch
regulation of tumor angiogenesis. Future Oncol. 7:569–588. 2011.
View Article : Google Scholar
|
|
11
|
Katoh M and Katoh M: WNT signaling pathway
and stem cell signaling network. Clin Cancer Res. 13:4042–4045.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Katoh Y and Katoh M: Hedgehog signaling,
epithelial-to-mesenchymal transition and miRNA (Review). Int J Mol
Med. 22:271–275. 2008.PubMed/NCBI
|
|
13
|
Rivkin E, Almeida SM, Ceccarelli DF, et
al: The linear ubiquitin-specific deubiquitinase gumby regulates
angiogenesis. Nature. 498:318–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Diehl AM: Neighborhood watch orchestrates
liver regeneration. Nat Med. 18:497–499. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katoh M and Nakagama H: FGF receptors:
cancer biology and therapeutics. Med Res Rev. May 21–2013.(Epub
ahead of print).
|
|
16
|
Dewhirst MW, Cao Y and Moeller B: Cycling
hypoxia and free radicals regulate angiogenesis and radiotherapy
response. Nat Rev Cancer. 8:425–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bao B, Azmi AS, Ali S, et al: The
biological kinship of hypoxia with CSC and EMT and their
relationship with deregulated expression of miRNAs and tumor
aggressiveness. Biochim Biophys Acta. 1826:272–296. 2012.PubMed/NCBI
|
|
18
|
Ferrara N, Hillan KJ and Novotny W:
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody
for cancer therapy. Biochem Biophys Res Commun. 333:328–335. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for
non-small-cell-lung cancer. N Engl J Med. 355:2542–2550. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schmitt J and Matei D: Targeting
angiogenesis in ovarian cancer. Cancer Treat Rev. 38:272–283. 2012.
View Article : Google Scholar
|
|
21
|
Hall M, Gourley C, McNeish I, et al:
Targeted anti-vascular therapies for ovarian cancer: current
evidence. Br J Cancer. 108:250–258. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chow LQ and Eckhardt SG: Sunitinib: from
rational design to clinical efficacy. J Clin Oncol. 25:884–896.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilhelm SM, Adnane L, Newell P, et al:
Preclinical overview of sorafenib, a multikinase inhibitor that
targets both Raf and VEGF and PDGF receptor tyrosine kinase
signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shojaei F: Anti-angiogenesis therapy in
cancer: current challenges and future perspectives. Cancer Lett.
320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bertolini F, Marighetti P, Martin-Padura
I, et al: Anti-VEGF and beyond: shaping a new generation of
anti-angiogenic therapies for cancer. Drug Discov Today.
16:1052–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Konecny GE, Kolarova T, O’Brien NA, et al:
Activity of the fibroblast growth factor receptor inhibitors
dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer
cells. Mol Cancer Ther. 12:632–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
O’Hare T, Shakespeare WC, Zhu X, et al:
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia,
potently inhibits the T315I mutant and overcomes mutation-based
resistance. Cancer Cell. 16:401–412. 2009.PubMed/NCBI
|
|
28
|
Gavine PR, Mooney L, Kilgour E, et al:
AZD4547: An orally bioavailable, potent and selective inhibitor of
the fibroblast growth factor receptor tyrosine kinase family.
Cancer Res. 72:2045–2056. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen HX and Cleck JN: Adverse effects of
anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol.
6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Penn JS, Madan A, Caldwell RB, et al:
Vascular endothelial growth factor in eye disease. Prog Retin Eye
Res. 27:331–371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rajagopalan S, Mohler ER 3rd, Lederman RJ,
et al: Regional angiogenesis with vascular endothelial growth
factor in peripheral arterial disease: a phase II randomized,
double-blind, controlled study of adenoviral delivery of vascular
endothelial growth factor 121 in patients with disabling
intermittent claudication. Circulation. 108:1933–1938. 2003.
|
|
32
|
Roth DA, McKirnan MD, Canestrelli I, et
al: Intracoronary delivery of an adenovirus encoding fibroblast
growth factor-4 in myocardial ischemia: effect of serum antibodies
and previous exposure to adenovirus. Hum Gene Ther. 17:230–238.
2006. View Article : Google Scholar
|
|
33
|
Sarkar N, Rück A, Källner G, et al:
Effects of intramyocardial injection of phVEGF-A165 as sole therapy
in patients with refractory coronary artery disease-12-month
follow-up: angiogenic gene therapy. J Intern Med. 250:373–381.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Belch J, Hiatt WR, Baumgartner I, et al:
Effect of fibroblast growth factor NV1FGF on amputation and death:
a randomised placebo-controlled trial of gene therapy in critical
limb ischaemia. Lancet. 377:1929–1937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Formiga FR, Tamayo E, Simón-Yarza T, et
al: Angiogenic therapy for cardiac repair based on protein delivery
systems. Heart Fail Rev. 17:449–473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoare TR and Kohane DS: Hydrogels in drug
delivery: Progress and challenges. Polymer. 49:1993–2007. 2008.
View Article : Google Scholar
|
|
37
|
Aranguren XL, McCue JD, Hendrickx B, et
al: Multipotent adult progenitor cells sustain function of ischemic
limbs in mice. J Clin Invest. 118:505–514. 2008.PubMed/NCBI
|
|
38
|
da Meirelles LS, Fontes AM, Covas DT and
Caplan AI: Mechanisms involved in the therapeutic properties of
mesenchymal stem cells. Cytokine Growth Factor Rev. 20:419–427.
2009.
|
|
39
|
Suzuki H, Shibata R, Kito T, et al:
Comparative angiogenic activities of induced pluripotent stem cells
derived from young and old mice. PLoS One. 7:e395622012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lichtenstein P, Holm NV, Verkasalo PK, et
al: Environmental and heritable factors in the causation of
cancer-analyses of cohorts of twins from Sweden, Denmark, and
Finland. N Engl J Med. 343:78–85. 2000. View Article : Google Scholar
|
|
41
|
Zimmet P, Alberti KG and Shaw J: Global
and societal implications of the diabetes epidemic. Nature.
414:782–787. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Eechoute K, van der Veldt AA, Oosting S,
et al: Polymorphisms in endothelial nitric oxide synthase (eNOS)
and vascular endothelial growth factor (VEGF) predict
sunitinib-induced hypertension. Clin Pharmacol Ther. 92:503–510.
2012.PubMed/NCBI
|
|
43
|
Scartozzi M, Bianconi M, Faloppi L, et al:
VEGF and VEGFR polymorphisms affect clinical outcome in advanced
renal cell carcinoma patients receiving first-line sunitinib. Br J
Cancer. 108:1126–1132. 2013.PubMed/NCBI
|
|
44
|
Petrovič MG, Korošec P, Košnik M, et al:
Local and genetic determinants of vascular endothelial growth
factor expression in advanced proliferative diabetic retinopathy.
Mol Vis. 14:1382–1387. 2008.PubMed/NCBI
|
|
45
|
Miles DW, de Haas SL, Dirix LY, et al:
Biomarker results from the AVADO phase 3 trial of first-line
bevacizumab plus docetaxel for HER2-negative metastatic breast
cancer. Br J Cancer. 108:1052–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome-biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ordovás JM and Smith CE: Epigenetics and
cardiovascular disease. Nat Rev Cardiol. 7:510–519. 2010.
|
|
48
|
Issa JP, Ahuja N, Toyota M, et al:
Accelerated age-related CpG island methylation in ulcerative
colitis. Cancer Res. 61:3573–3577. 2001.PubMed/NCBI
|
|
49
|
Kang GH, Lee HJ, Hwang KS, et al: Aberrant
CpG island hypermethylation of chronic gastritis, in relation to
aging, gender, intestinal metaplasia, and chronic inflammation. Am
J Pathol. 163:1551–1556. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rivenbark AG and Coleman WB: Field
cancerization in mammary carcinogenesis - Implications for
prevention and treatment of breast cancer. Exp Mol Pathol.
93:391–398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wittmann J and Jäck HM: Serum microRNAs as
powerful cancer biomarkers. Biochim Biophys Acta. 1806:200–207.
2010.PubMed/NCBI
|
|
52
|
Kuehbacher A, Urbich C and Dimmeler S:
Targeting microRNA expression to regulate angiogenesis. Trends
Pharmacol Sci. 29:12–15. 2008. View Article : Google Scholar
|
|
53
|
Wang S and Olson EN: AngiomiRs - key
regulators of angiogenesis. Curr Opin Genet Dev. 19:205–211. 2009.
View Article : Google Scholar
|
|
54
|
Gallo A, Tandon M, Alevizos I and Illei
GG: The majority of microRNAs detectable in serum and saliva is
concentrated in exosomes. PLoS One. 7:e306792012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Turchinovich A, Weiz L and Burwinkel B:
Extracellular miRNAs: the mystery of their origin and function.
Trends Biochem Sci. 37:460–465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Banigan MG, Kao PF, Kozubek JA, et al:
Differential expression of exosomal microRNAs in prefrontal
cortices of schizophrenia and bipolar disorder patients. PLoS One.
8:e488142013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cantaluppi V, Gatti S, Medica D, et al:
Microvesicles derived from endothelial progenitor cells protect the
kidney from ischemia-reperfusion injury by microRNA-dependent
reprogramming of resident renal cells. Kidney Int. 82:412–427.
2012. View Article : Google Scholar
|
|
58
|
Lässer C: Exosomal RNA as biomarkers and
the therapeutic potential of exosome vectors. Expert Opin Biol
Ther. 12(Suppl 1): S189–S197. 2012.PubMed/NCBI
|
|
59
|
Qin D, Trenkwalder T, Lee S, et al: Early
vessel destabilization mediated by Angiopoietin-2 and subsequent
vessel maturation via Angiopoietin-1 induce functional
neovasculature after ischemia. PLoS One. 8:e618312013. View Article : Google Scholar
|
